Table 5.

One-way sensitivity analyses comparing cervical cancer screening only and cervical cancer screening associated with a quadrivalent HPV vaccination programme

Parameters	ICER (£/QALYs)	ICER (£/LYs)
Base case	21,059	34,687
Vaccine duration
10 years	68,417	116,743
10 years + booster to achieve lifetime protection	26,782	44,114
20 years	30,777	52,578
Multiple infections
15%	24,085	39,842
Vaccine efficacy
85%	25,081	40,831
Vaccine coverage
50%	21,581	34,426
Screening coverage rate
-50%	16,266.	35,476
-10%	19,926	34,681
Screening, diagnosis and treatment costs
-20%	21,717	35,771
+20%	20,401	33,602
Vaccine costs
70 £	19,450	32,036
80 £	22,668	37,337
Utilities
25% decrease for screening utilities; 1-year duration for time with cancer	25,600
25% increase in time with disease; 5-year duration for time with cancer	19,840
Cancer utilities only (5 year duration)	27,954
Discount rates
0% costs; 0% medical benefit	3,123	4,122
3% costs; 3% medical benefit	17,089	27,066
3,5% costs; 1,5% medical benefit	9,653	13,797
5% costs; 5% medical benefit	36,618	68,760
Multivariate Sensitivity Analyses
10 years duration, 50% coverage, 85% efficacy	84,925	140,705
Lifetime duration, 90% coverage, 100% efficacy	20,316	33,752
Changes to Screening (assuming base case assumptions for the vaccine)
Screening every 5 years starting at age 25	13,449	36,712
Screening starting at age 26	20,724	34,441
Screening starting at age 28	16,527	34,153
Screening starting at age 30	13,680	34,989

Base case discount rate: 3.5% for costs and medical benefits